July 22, 2016 / 6:07 AM / a year ago

BRIEF-Valeant says no safety concerns, additional clinical trials for approval of Latanoprostene Bunod

July 22 (Reuters) - Valeant Pharmaceuticals International Inc

* Concerns raised by fda pertain to good manufacturing practice inspection at bausch+lomb’s facility in florida where deficiencies were identified

* Valeant pharmaceuticals receives complete response letter from the fda

* Fda’s letter did not identify any efficacy or safety concerns with respect to nda or additional clinical trials needed for approval of nda

* Intends to meet with fda as soon as possible to work on a resolution and address these concerns

* No safety or efficacy concerns or additional clinical trials identified for approval of latanoprostene bunod Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below